Theravance Biopharma (NASDAQ:TBPH) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen cut shares of Theravance Biopharma (NASDAQ:TBPH) from a buy rating to a hold rating in a report published on Saturday.

A number of other research firms have also commented on TBPH. TD Cowen boosted their price objective on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, March 23rd. Zacks Research raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Thursday, March 19th. B. Riley Financial boosted their price objective on Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 7th. Oppenheimer lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Finally, Weiss Ratings lowered Theravance Biopharma from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $21.83.

Theravance Biopharma Stock Performance

Theravance Biopharma stock opened at $16.22 on Friday. The firm has a market cap of $836.14 million, a P/E ratio of 7.37 and a beta of 0.19. The business’s fifty day moving average is $15.74 and its two-hundred day moving average is $17.45. Theravance Biopharma has a 52 week low of $9.04 and a 52 week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. On average, equities research analysts predict that Theravance Biopharma will post 0.95 earnings per share for the current year.

Insider Activity

In other news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.65% of the stock is owned by company insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several large investors have recently made changes to their positions in TBPH. AQR Capital Management LLC bought a new stake in Theravance Biopharma in the first quarter valued at about $101,000. Jane Street Group LLC increased its holdings in Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 88,540 shares during the last quarter. Creative Planning bought a new stake in Theravance Biopharma in the second quarter valued at about $139,000. American Century Companies Inc. increased its holdings in Theravance Biopharma by 6.8% in the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock valued at $1,009,000 after purchasing an additional 5,794 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Theravance Biopharma by 12.4% in the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,789 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.